Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Tezacaftor/Ivacaftor in Children ≥6 Years of Age With F508del and Residual Function Changes in CFTR.

Tezacaftor/Ivacaftor in Children ≥6 Years of Age With F508del and Residual Function Changes in CFTR.

Resource Type

CF Research News

Authors

Gregory S Sawicki, Mark Chilvers, John McNamara, Lutz Naehrlich, Clare Saunders, Isabelle Sermet-Gaudelus, Claire E Wainwright, Neil Ahluwalia, Daniel Campbell, R Scott Harris, Hildegarde Paz-Diaz, Judy L Shih, Jane C Davies

References

J Cyst Fibros. 2022 Feb 18;S1569-1993(22)00033-9. doi: 10.1016/j.jcf.2022.02.003.
 

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Theme

Care of patients with CF [3]
Clinical Trials [4]
Pulmonology [5]

Keywords

Ivacaftor [6]
Tezacaftor [7]

Date

Friday, February 18, 2022

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/tezacaftorivacaftor-children-%E2%89%A56-years-age-f508del-and-residual

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-21-00472R1_FINAL_Sawicki_120322.pdf [2] https://pubmed.ncbi.nlm.nih.gov/35190292/ [3] https://www.ecfs.eu/research-article-themes/care-patients-cf [4] https://www.ecfs.eu/research-article-themes/clinical-trials [5] https://www.ecfs.eu/research-article-themes/pulmonology [6] https://www.ecfs.eu/research-article-keywords/ivacaftor [7] https://www.ecfs.eu/research-article-keywords/tezacaftor [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines